What is a stock summary page? Click here for an overview.
Business Description
Auro Laboratories Ltd
ISIN : INE292C01011
Share Class Description:
BOM:530233: Shs DematerialisedCompare
Compare
Traded in other countries / regions
530233.India IPO Date
2000-11-13Description
Auro Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and selling of pharmaceutical products like Metformin Hydrochloride and Glibenclamide. The pharmaceutical products range offered by the company are anti-diabetic, muscle relaxant, diuretic, iron deficiency anti-fungal, anti-ulcer, iodine supplement, anti-malaria, antacids, anti-inflammatory, specialty chemicals, and others. The company sells its products in India and also exports it to international countries.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.79 | |||||
| Debt-to-EBITDA | 5.75 | |||||
| Interest Coverage | 8.4 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.96 | |||||
| Beneish M-Score | -3.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.1 | |||||
| 3-Year EBITDA Growth Rate | 0.5 | |||||
| 3-Year EPS without NRI Growth Rate | 2.8 | |||||
| 3-Year Book Growth Rate | 13.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.4 | |||||
| 9-Day RSI | 46.01 | |||||
| 14-Day RSI | 50.32 | |||||
| 3-1 Month Momentum % | -5.49 | |||||
| 6-1 Month Momentum % | 8.31 | |||||
| 12-1 Month Momentum % | 19.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.75 | |||||
| Quick Ratio | 1.21 | |||||
| Cash Ratio | 0.68 | |||||
| Days Inventory | 330.6 | |||||
| Days Sales Outstanding | 155.9 | |||||
| Days Payable | 161.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -12.14 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.89 | |||||
| Operating Margin % | 16.55 | |||||
| Net Margin % | 15.41 | |||||
| FCF Margin % | -73.18 | |||||
| ROE % | 8.69 | |||||
| ROA % | 4.59 | |||||
| ROIC % | 4.92 | |||||
| 3-Year ROIIC % | 0.47 | |||||
| ROC (Joel Greenblatt) % | 8.23 | |||||
| ROCE % | 8.06 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 42.93 | |||||
| PE Ratio without NRI | 42.93 | |||||
| Shiller PE Ratio | 34.01 | |||||
| Price-to-Owner-Earnings | 24.83 | |||||
| PEG Ratio | 26.83 | |||||
| PS Ratio | 6.64 | |||||
| PB Ratio | 3.51 | |||||
| Price-to-Tangible-Book | 3.52 | |||||
| Price-to-Operating-Cash-Flow | 8.08 | |||||
| EV-to-EBIT | 36.68 | |||||
| EV-to-EBITDA | 29.96 | |||||
| EV-to-Revenue | 7.75 | |||||
| EV-to-FCF | -10.99 | |||||
| Price-to-GF-Value | 4.8 | |||||
| Price-to-Projected-FCF | 4.24 | |||||
| Price-to-DCF (Earnings Based) | 1.66 | |||||
| Price-to-Median-PS-Value | 6.88 | |||||
| Price-to-Graham-Number | 1.96 | |||||
| Earnings Yield (Greenblatt) % | 2.73 | |||||
| FCF Yield % | -11.03 | |||||
| Forward Rate of Return (Yacktman) % | -0.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Auro Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 230.036 | ||
| EPS (TTM) (₹) | 5.68 | ||
| Beta | 0.27 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 1.37 | ||
| Volatility % | 66.98 | ||
| 14-Day RSI | 50.32 | ||
| 14-Day ATR (₹) | 17.384879 | ||
| 20-Day SMA (₹) | 246.8525 | ||
| 12-1 Month Momentum % | 19.28 | ||
| 52-Week Range (₹) | 156.4 - 307.2 | ||
| Shares Outstanding (Mil) | 6.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Auro Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Auro Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Auro Laboratories Ltd Frequently Asked Questions
What is Auro Laboratories Ltd(BOM:530233)'s stock price today?
The current price of BOM:530233 is ₹244.90. The 52 week high of BOM:530233 is ₹307.20 and 52 week low is ₹156.40.
When is next earnings date of Auro Laboratories Ltd(BOM:530233)?
The next earnings date of Auro Laboratories Ltd(BOM:530233) is .
Does Auro Laboratories Ltd(BOM:530233) pay dividends? If so, how much?
Auro Laboratories Ltd(BOM:530233) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers